Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study of NS-863 in subjects with renal impairment
jRCT2031260138Phase 1Recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NS-863 in chronic kidney disease (CKD) (2 cohorts), sponsored by Nippon Shinyaku. Primary endpoints: Plasma concentration and PK parameters of NS-863, Plasma unbound fraction of NS-863 and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
NS-863
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031260138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260138.